{"id":250986,"date":"2025-03-25T00:00:00","date_gmt":"2025-03-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidhe0001-biopharma-beta-thalassemia-epidemiology-mature-markets\/"},"modified":"2026-04-28T11:12:07","modified_gmt":"2026-04-28T11:12:07","slug":"epidhe0001-biopharma-beta-thalassemia-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidhe0001-biopharma-beta-thalassemia-epidemiology-mature-markets\/","title":{"rendered":"Beta Thalassemia &#8211; Epidemiology &#8211; Mature markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of beta thalassemia (<abbr title=\"beta thalassemia\">BT<\/abbr>) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"beta thalassemia\">BT<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"beta thalassemia\">BT<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"beta thalassemia\">BT<\/abbr>?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"beta thalassemia\">BT<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 30 <abbr title=\"beta thalassemia\">BT<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed <abbr title=\"beta thalassemia\">BT<\/abbr> prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"beta thalassemia\">BT<\/abbr> major prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"beta thalassemia\">BT<\/abbr> intermedia prevalent cases.<\/li>\n<li>Diagnosed B0\/B0 <abbr title=\"beta thalassemia\">BT<\/abbr> major prevalent cases.<\/li>\n<li>Diagnosed B0\/B+ <abbr title=\"beta thalassemia\">BT<\/abbr> major prevalent cases.<\/li>\n<li>Diagnosed B+\/B+ <abbr title=\"beta thalassemia\">BT<\/abbr> major prevalent cases.<\/li>\n<li>Diagnosed B0\/B0 <abbr title=\"beta thalassemia\">BT<\/abbr> major prevalent cases with matched related <abbr title=\"hematopoietic stem cell\">HSC<\/abbr> transplantation \u2013 younger than 12 years old.<\/li>\n<li>Diagnosed B0\/B0 <abbr title=\"beta thalassemia\">BT<\/abbr> major prevalent cases with matched related <abbr title=\"hematopoietic stem cell\">HSC<\/abbr> transplantation \u2013 12 years of age or older.<\/li>\n<li>Diagnosed B0\/B0 <abbr title=\"beta thalassemia\">BT<\/abbr> prevalent cases without matched related <abbr title=\"hematopoietic stem cell\">HSC<\/abbr> transplantation \u2013 younger than 12 years old.<\/li>\n<li>Diagnosed B0\/B0 <abbr title=\"beta thalassemia\">BT<\/abbr> prevalent cases without matched related <abbr title=\"hematopoietic stem cell\">HSC<\/abbr> transplantation \u2013 12 years of age or older.<\/li>\n<li>Diagnosed <abbr title=\"beta thalassemia\">BT<\/abbr> intermedia prevalent cases requiring transfusions.<\/li>\n<li>Diagnosed <abbr title=\"beta thalassemia\">BT<\/abbr> major pediatric prevalent cases.<\/li>\n<li>Diagnosed <abbr title=\"beta thalassemia\">BT<\/abbr> major adult prevalent cases.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250986","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250986\/revisions"}],"predecessor-version":[{"id":501982,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250986\/revisions\/501982"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}